{
  "trial_id": "NCT03023059",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "A diagnosis of AMD with choroidal neovascularization (CNV) in one eye",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Normal or dry AMD of any grade in the second eye",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Willingness to maintain AREDS vitamin supplements throughout the study, or remain off these supplements for the duration of the study, if not taking them prior to the study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Informed Consent at Baseline",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Any current use of L-DOPA containing medication or dopamine agonist medication, or any planned use of any of these agents, except for study medication, during the study",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Concurrent use of monoamine oxidase (MAO) inhibitors",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "The patient has a known history of sickle cell disease and is experiencing severe bone pain. He has been treated with oxycodone in the past two weeks, but it was not beneficial.",
  "_meta": {
    "topic_id": "45",
    "trial_id": "NCT03023059",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}